Mylan gets Fed Circ reprieve in inhaler dispute

09-12-2021

Muireann Bolger

Mylan gets Fed Circ reprieve in inhaler dispute

ricochet64 / Shutterstock.com

In a win for Mylan Pharmaceuticals, a US Court of Appeals for the Federal Circuit panel has ruled it can revisit a decision that held the generic maker infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort.


Mylan, patents, AstraZeneca, construction, claim, Symbicort, Turbohaler, Federal Circuit, remand, generic, asthma, treatment

LSIPR